I apply every IPO with full force which has QIB Sub >15. Losses are limited to 5-10% which happens very rarely but upside is very high 20-100% . so risk to reward ratio is very high . Markets are all about probabilities and stats baki sab baatein hain ''Aisa hota toh vaise hota''
@NITEENIPO Apply only for Mainstream IPO size is >200cr. This the statistical analysis done over last 5 years IPO. As i said , If risk reward ratio is good than there is an edge. Markets are irrational so i keep things very simple
Clean Science , Tatva, Ami Organics, Glenmark Lifesciences, Windlass and Supriya Lifesciences all filed DRHP almost at the same time. All got approvals . With the exception of Supriya Lifesciences , all have hit the IPO Market. it is a mystery why Supriya Lifesciences has not hit IPO Market ?
Key Points β 1. Two Product Contribute 44% of Revenue β Trazodone β Dolutegravir 2. 44.4% of revenue from Top Five Customers. 3. 34.58% Purchase from Top Five Suppliers. 4. Forex Risk as 50% is export sales.
Why are QIB not applying in large. Only 1.49 times till now. Seems ther are more scared than us retailers. Between I applied for 6 lots from 6 accounts.